Spore-ing change: Rua Bioscience psilocybin study targets meth addiction

Spore-ing change: Rua Bioscience psilocybin study targets meth addiction
Gisborne-based pharmaceutical company Rua Bioscience is hoping mushrooms can help cure meth addiction. (Image: Supplied)
Gregor Thompson
Rua Bioscience is exploring psilocybin-containing mushrooms’ potential in treating methamphetamine addiction.The clinical study, dubbed Tū Wairua (standing with strength and spiritual connectedness), intends to combine historic Māori practices with modern science to tackle meth addiction.The New Zealand Exchange-listed (NZX) and the Gisborne-based medical cannabis company announced Phase I of the new trial on Tuesday.“Over the past week, the first cohort of marae-based participants engaged in preparatory and experiential sessio...

More Markets

Vital takeover bid passes threshold at 11th hour
Markets

Vital takeover bid passes threshold at 11th hour

Tait International has secured acceptances to meet the 90% minimum condition for its Vital takeover less than a day before the offer was set to expire.Vital filed a substantial product holder (SPH) notice to the NZX on Friday morning, which showed Tait's stake lifted to 92.1%...

Tower again hikes FY underlying profit outlook
Markets

Tower again hikes FY underlying profit outlook

Insurer sees FY underling profit up as large events weigh less than expected     

F&P Healthcare one step closer to new Karaka campus
Policy

F&P Healthcare one step closer to new Karaka campus

Auckland Council has approved a request to rezone nearly 90ha going to hearings.

Briscoe Group half-year splits analysts
Retail

Briscoe Group half-year splits analysts

Forsyth Barr says the stock is “quality but expensive”.